CN Patent

CN108601767A — 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法

Assigned to Calithera Biosciences Inc · Expires 2018-09-28 · 8y expired

What this patent protects

本发明涉及用谷氨酰胺酶抑制剂和免疫肿瘤学治疗剂的组合治疗癌症、骨髓增生性疾病或免疫或神经疾病的方法，所述免疫肿瘤学治疗剂例如精氨酸酶、CTLA‑4、吲哚胺2,3‑双加氧酶和/或PD‑1/PD‑L1的抑制剂。

USPTO Abstract

本发明涉及用谷氨酰胺酶抑制剂和免疫肿瘤学治疗剂的组合治疗癌症、骨髓增生性疾病或免疫或神经疾病的方法，所述免疫肿瘤学治疗剂例如精氨酸酶、CTLA‑4、吲哚胺2,3‑双加氧酶和/或PD‑1/PD‑L1的抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN108601767A
Jurisdiction
CN
Classification
—
Expires
2018-09-28
Drug substance claim
No
Drug product claim
No
Assignee
Calithera Biosciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.